BIOVERSYS
Bioversys AG is a privately held Swiss biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch-off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, we have profound technological expertise that is based on solid IP.
BIOVERSYS
Industry:
Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.bioversys.com
Total Employee:
1+
Status:
Active
Contact:
+41 78 670 40 85
Email Addresses:
[email protected]
Total Funding:
90.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
NPK Biotest
NPK Biotest is a privately held pharmaceutical company.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Obexia
Obexia is a privately held biopharmaceuticals start-up company based in Basel.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - BioVersys
European Investment Bank
European Investment Bank investment in Debt Financing - BioVersys
Business Angels Switzerland (BAS)
Business Angels Switzerland (BAS) investment in Series B - BioVersys
CARB-X
CARB-X investment in Grant - BioVersys
Business Angels Switzerland (BAS)
Business Angels Switzerland (BAS) investment in Series A - BioVersys
GoBeyond
GoBeyond investment in Seed Round - BioVersys
BioValley Business Angels Club (BioBAC)
BioValley Business Angels Club (BioBAC) investment in Seed Round - BioVersys
EVA Basel
EVA Basel investment in Seed Round - BioVersys
Venture Kick
Venture Kick investment in Pre Seed Round - BioVersys
Venture Kick
Venture Kick investment in Grant - BioVersys
Newest Events participated
Official Site Inspections
http://www.bioversys.com Semrush global rank: 8.53 M Semrush visits lastest month: 300
- Host name: chaplin.sui-inter.net
- IP address: 94.126.16.60
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "BioVersys"
Team | Meet the Resistance Fighters - www.bioversys.com
Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance …See details»
BioVersys - Crunchbase Company Profile & Funding
Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved …See details»
Patients - BioVersys
Saving Lives in Resistant Times: BioVersys' mission to provide lifesaving medicines and address the Antimicrobial Resistance crisis. At BioVersys, we are fully aware of the urgent nature of our mission.See details»
BioVersys AG – Swiss Biotech
BioVersys AG is a privately held Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.See details»
BioVersys AG - LinkedIn
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and …See details»
BioVersys AG - Devex
The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics.See details»
BioVersys Company Profile 2024: Valuation, Funding & Investors
The company's platform addresses the medical need for new treatments against life-threatening bacterial infections that emerged in recent years due to the resistance of bacterial strains …See details»
BioVersys - Funding, Financials, Valuation & Investors - Crunchbase
BioVersys develops novel antibacterial products to combat serious life-threatening infections caused by MDR bacteria.See details»
BioVersys Company Profile - Office Locations, Competitors ... - Craft
BioVersys is a company that develops drugs and compounds. The company focuses on research and development of new drugs and compounds, which switch-off drug resistance within …See details»
OpGen Subsidiary Curetis and BioVersys Sign Collaboration …
Oct 25, 2022 Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys commented: “Rapid diagnostics such as the Curetis Unyvero platform are increasingly becoming integral to …See details»
Antimicrobial Resistance - BioVersys
The Swiss biopharmaceutical company BioVersys focuses on research and development of molecules to switch off resistance against antibiotics.See details»
BioVersys: saving lives in resistant times - media.nature.com
The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria.See details»
BioVersys: saving lives in resistant times - Nature
The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria.See details»
BioVersys Works to Bring Antibiotic Resistance to an End
BioVersys, founded in 2008, is working on bringing a technology for screening and for the development of 'transcriptional regulator inhibiting compounds' (TRICs) to patients in order to …See details»
BioVersys Announces Expansion of Strategic Collaboration With …
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries …See details»
BioVersys AG - startup.ch
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterials for life-threatening infections caused by multi-drug resistant (“MDR”) …See details»
Fighting the World's Largest Infectious Disease - BioVersys
TB remains a formidable Global Health challenge particularly considering the fact that about 1.7 billion people, 23% of the world’s population, are estimated to have a latent TB infection, and …See details»
BioVersys: More collaboration with GSK and series C ... - Swiss …
May 7, 2024 BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections …See details»
News - BioVersys
BioVersys in the News. News. BioVersys Joins Eu-Funded RespiriNTM Programme to Accelerate Development of its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases. …See details»